Skip to main content
Erschienen in: Drug Safety 1/2013

01.10.2013 | Original Research Article

Empirical Performance of the Calibrated Self-Controlled Cohort Analysis Within Temporal Pattern Discovery: Lessons for Developing a Risk Identification and Analysis System

verfasst von: G. Niklas Norén, Tomas Bergvall, Patrick B. Ryan, Kristina Juhlin, Martijn J. Schuemie, David Madigan

Erschienen in: Drug Safety | Sonderheft 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Observational healthcare data offer the potential to identify adverse drug reactions that may be missed by spontaneous reporting. The self-controlled cohort analysis within the Temporal Pattern Discovery framework compares the observed-to-expected ratio of medical outcomes during post-exposure surveillance periods with those during a set of distinct pre-exposure control periods in the same patients. It utilizes an external control group to account for systematic differences between the different time periods, thus combining within- and between-patient confounder adjustment in a single measure.

Objectives

To evaluate the performance of the calibrated self-controlled cohort analysis within Temporal Pattern Discovery as a tool for risk identification in observational healthcare data.

Research Design

Different implementations of the calibrated self-controlled cohort analysis were applied to 399 drug-outcome pairs (165 positive and 234 negative test cases across 4 health outcomes of interest) in 5 real observational databases (four with administrative claims and one with electronic health records).

Measures

Performance was evaluated on real data through sensitivity/specificity, the area under receiver operator characteristics curve (AUC), and bias.

Results

The calibrated self-controlled cohort analysis achieved good predictive accuracy across the outcomes and databases under study. The optimal design based on this reference set uses a 360 days surveillance period and a single control period 180 days prior to new prescriptions. It achieved an average AUC of 0.75 and AUC >0.70 in all but one scenario. A design with three separate control periods performed better for the electronic health records database and for acute renal failure across all data sets. The estimates for negative test cases were generally unbiased, but a minor negative bias of up to 0.2 on the RR-scale was observed with the configurations using multiple control periods, for acute liver injury and upper gastrointestinal bleeding.

Conclusions

The calibrated self-controlled cohort analysis within Temporal Pattern Discovery shows promise as a tool for risk identification; it performs well at discriminating positive from negative test cases. The optimal parameter configuration may vary with the data set and medical outcome of interest.
Literatur
1.
Zurück zum Zitat Edwards IR, Lindquist M, Wiholm BE, Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet. 1990;336(8708):156–8.PubMedCrossRef Edwards IR, Lindquist M, Wiholm BE, Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet. 1990;336(8708):156–8.PubMedCrossRef
2.
Zurück zum Zitat Rawlins MD. Spontaneous reporting of adverse drug reactions. I: the data. Brit J Clin Pharmacol. 1988;26(1):1–5.CrossRef Rawlins MD. Spontaneous reporting of adverse drug reactions. I: the data. Brit J Clin Pharmacol. 1988;26(1):1–5.CrossRef
3.
Zurück zum Zitat Meyboom RH, Lindquist M, Egberts AC. An ABC of drug-related problems. Drug Saf. 2000;22(6):415–23.PubMedCrossRef Meyboom RH, Lindquist M, Egberts AC. An ABC of drug-related problems. Drug Saf. 2000;22(6):415–23.PubMedCrossRef
4.
Zurück zum Zitat Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539–46.PubMedCrossRef Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539–46.PubMedCrossRef
5.
Zurück zum Zitat Public Law 110-85: Food and Drug Administration Amendments Act of 2007. 2007. Public Law 110-85: Food and Drug Administration Amendments Act of 2007. 2007.
6.
Zurück zum Zitat Woodcock J, Behrman RE, Dal Pan GJ. Role of postmarketing surveillance in contemporary medicine. Annu Rev Med. 2011;62:1–10.PubMedCrossRef Woodcock J, Behrman RE, Dal Pan GJ. Role of postmarketing surveillance in contemporary medicine. Annu Rev Med. 2011;62:1–10.PubMedCrossRef
7.
Zurück zum Zitat Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20(3):361–87.CrossRef Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20(3):361–87.CrossRef
8.
Zurück zum Zitat Norén GN, Bate A, Hopstadius J, Star K, Edwards IR. Temporal pattern discovery for trends and transient effects: its application to patient records. In: ACM SIGKDD international conference on knowledge discovery and data mining, KDD ‘08. Las Vegas: ACM; 2008. p. 963–71. Norén GN, Bate A, Hopstadius J, Star K, Edwards IR. Temporal pattern discovery for trends and transient effects: its application to patient records. In: ACM SIGKDD international conference on knowledge discovery and data mining, KDD ‘08. Las Vegas: ACM; 2008. p. 963–71.
10.
Zurück zum Zitat Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401–15.PubMedCrossRef Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401–15.PubMedCrossRef
11.
Zurück zum Zitat Norén GN, Hopstadius J, Bate A, Edwards IR. Safety surveillance of longitudinal databases: results on real-world data. Pharmacoepidemiol Drug Saf. 2012;21(6):673–5.CrossRef Norén GN, Hopstadius J, Bate A, Edwards IR. Safety surveillance of longitudinal databases: results on real-world data. Pharmacoepidemiol Drug Saf. 2012;21(6):673–5.CrossRef
12.
Zurück zum Zitat Schuemie MJ. Safety surveillance of longitudinal databases: further methodological considerations. Pharmacoepidemiol Drug Saf. 2012;21(6):670–2.PubMedCrossRef Schuemie MJ. Safety surveillance of longitudinal databases: further methodological considerations. Pharmacoepidemiol Drug Saf. 2012;21(6):670–2.PubMedCrossRef
13.
Zurück zum Zitat Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013 (in this supplement issue). doi:10.1007/s40264-013-0097-8. Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013 (in this supplement issue). doi:10.​1007/​s40264-013-0097-8.
14.
Zurück zum Zitat Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.CrossRef Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.CrossRef
15.
Zurück zum Zitat Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013 (in this supplement issue). doi:10.1007/s40264-013-0101-3. Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013 (in this supplement issue). doi:10.​1007/​s40264-013-0101-3.
16.
Zurück zum Zitat Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7:5.CrossRef Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7:5.CrossRef
17.
Zurück zum Zitat Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol. 1996;143(11):1165–73.PubMedCrossRef Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol. 1996;143(11):1165–73.PubMedCrossRef
18.
Zurück zum Zitat Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144–53.PubMed Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144–53.PubMed
19.
Zurück zum Zitat Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ. 2009;338:b81.PubMedCrossRef Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ. 2009;338:b81.PubMedCrossRef
20.
Zurück zum Zitat Schuemie MJ. Safety surveillance of longitudinal databases: further methodological considerations. Pharmacoepidemiol Drug Saf. 2012;21(6):670–2. doi:10.1002/pds.3259. Schuemie MJ. Safety surveillance of longitudinal databases: further methodological considerations. Pharmacoepidemiol Drug Saf. 2012;21(6):670–2. doi:10.​1002/​pds.​3259.
21.
Zurück zum Zitat Tisdale J, Miller D. Drug-induced diseases: prevention, detection, and management. 2nd ed. USA: American Society of Health-System Pharmacists; 2010. Tisdale J, Miller D. Drug-induced diseases: prevention, detection, and management. 2nd ed. USA: American Society of Health-System Pharmacists; 2010.
22.
Zurück zum Zitat Armstrong B. A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies. Am J Epidemiol. 1987;126(2):356–8.PubMedCrossRef Armstrong B. A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies. Am J Epidemiol. 1987;126(2):356–8.PubMedCrossRef
23.
Zurück zum Zitat Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839–43.PubMed Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839–43.PubMed
24.
Zurück zum Zitat Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ. 2011;183(3):E173–9.PubMedCrossRef Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ. 2011;183(3):E173–9.PubMedCrossRef
25.
Zurück zum Zitat Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med. 1993;119(7 Pt 1):576–83.PubMedCrossRef Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med. 1993;119(7 Pt 1):576–83.PubMedCrossRef
26.
Zurück zum Zitat Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22(1):39–56.PubMedCrossRef Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22(1):39–56.PubMedCrossRef
27.
Zurück zum Zitat Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69.PubMedCrossRef Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69.PubMedCrossRef
Metadaten
Titel
Empirical Performance of the Calibrated Self-Controlled Cohort Analysis Within Temporal Pattern Discovery: Lessons for Developing a Risk Identification and Analysis System
verfasst von
G. Niklas Norén
Tomas Bergvall
Patrick B. Ryan
Kristina Juhlin
Martijn J. Schuemie
David Madigan
Publikationsdatum
01.10.2013
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe Sonderheft 1/2013
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-013-0095-x

Weitere Artikel der Sonderheft 1/2013

Drug Safety 1/2013 Zur Ausgabe